These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2265874)

  • 1. The drug swindlers.
    Silverman M; Lydecker M; Lee PR
    Int J Health Serv; 1990; 20(4):561-72. PubMed ID: 2265874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug promotion and labeling in developing countries: an update.
    Lee PR; Lurie P; Silverman MM; Lydecker M
    J Clin Epidemiol; 1991; 44 Suppl 2():49S-55S. PubMed ID: 2045842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The drugging of the Third World.
    Silverman M; Lee PR; Lydecker M
    Int J Health Serv; 1982; 12(4):585-96. PubMed ID: 7141775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tackling corruption in the pharmaceutical systems worldwide with courage and conviction.
    Cohen JC; Mrazek M; Hawkins L
    Clin Pharmacol Ther; 2007 Mar; 81(3):445-9. PubMed ID: 17251983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical marketing practices: balancing public health and law enforcement interests; moving beyond regulation-through-litigation.
    Zalesky CD
    J Health Law; 2006; 39(2):235-64. PubMed ID: 17002233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A doctor's drug studies turn into fraud.
    Eichenwald K; Kolata G
    N Y Times Web; 1999 May; ():A1, A16. PubMed ID: 11647660
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceuticals and Medical Devices: Business Practices.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-37. PubMed ID: 27116796
    [No Abstract]   [Full Text] [Related]  

  • 9. Counterfeit and substandard drugs in India may be smaller problem than claimed, say government findings.
    Travasso C
    BMJ; 2014 Jan; 348():g60. PubMed ID: 25489932
    [No Abstract]   [Full Text] [Related]  

  • 10. Brands or generics: the dilemma of pharmaceutical marketing in a developing country.
    Quraeshi ZA; Luqmani M; Malhotra N
    J Health Care Mark; 1983; 3(4):27-37. PubMed ID: 10264767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of online pharmacy: an Australian perspective.
    Bernath P
    J Law Med; 2003 Feb; 10(3):339-63. PubMed ID: 12650004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in pharmaceutical products liability law: failure to warn, the learned intermediary defense, and other issues in the new millennium.
    Garbutt BJ; Hofmann ME
    Food Drug Law J; 2003; 58(2):269-86. PubMed ID: 12866558
    [No Abstract]   [Full Text] [Related]  

  • 13. Corruption and use of antibiotics in regions of Europe.
    Rönnerstrand B; Lapuente V
    Health Policy; 2017 Mar; 121(3):250-256. PubMed ID: 28094050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experts blame feds for pharma corruption.
    Vogel L
    CMAJ; 2017 Feb; 189(8):E327-E328. PubMed ID: 28246233
    [No Abstract]   [Full Text] [Related]  

  • 15. Current development in regulation of similar biotherapeutic products in Brazil.
    Castanheira LG; Barbano DB; Rech N
    Biologicals; 2011 Sep; 39(5):308-11. PubMed ID: 21868247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 17. ASEAN GMP and pharmaceutical industries in Indonesia.
    Soesilo S; Sitorus U
    PDA J Pharm Sci Technol; 1995; 49(4):192-5. PubMed ID: 7552240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restrictions on the conduct of advertising of medicinal products in Poland and their violations.
    Czerw A; Marek EM
    Acta Pol Pharm; 2013; 70(4):769-76. PubMed ID: 23923402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indian generics manufacturer Ranbaxy agrees to pay $500m to settle US fraud and drug safety charges.
    Kay M
    BMJ; 2013 May; 346():f3536. PubMed ID: 23723460
    [No Abstract]   [Full Text] [Related]  

  • 20. Counterfeit drugs: implications for health.
    ten Ham M
    Adverse Drug React Toxicol Rev; 1992; 11(1):59-65. PubMed ID: 1606284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.